Search

Your search keyword '"Itzhar-Baikian, Nathalie"' showing total 11 results
Start Over Author "Itzhar-Baikian, Nathalie"
11 results on '"Itzhar-Baikian, Nathalie"'

4. Gastrointestinal bleeding from angiodysplasia in von Willebrand disease: Improved diagnosis and outcome prediction using videocapsule on top of conventional endoscopy

Author

Rauch, Antoine, Paris, Camille, Repesse, Yohann, Branche, Julien, D’Oiron, Roseline, Harroche, Annie, Ternisien, Catherine, Castet, Sabine‐Marie, Lebreton, Aurélien, Pan‐Petesch, Brigitte, Volot, Fabienne, Claeyssens, Segolene, Chamouni, Pierre, Gay, Valérie, Berger, Claire, Desprez, Dominique, Falaise, Céline, Biron Andreani, Christine, Marichez, Catherine, Pradines, Benedicte, Zawadzki, Christophe, Itzhar Baikian, Nathalie, Borel‐Derlon, Annie, Goudemand, Jenny, Gerard, Romain, and Susen, Sophie

Published
2021
Full Text
View/download PDF

5. Management of von Willebrand disease with a factor VIII‐poor von Willebrand factor concentrate: Results from a prospective observational post‐marketing study

Author

Itzhar‐baïkian, Nathalie, Borel‐derlon, Annie, Goudemand, Jenny, Bridey, Françoise, Claeyssens, Segolene, Itzhar-Baikian, Nathalie, Harroche, Annie, Desprez, Dominique, Negrier, Claude, Chamouni, Pierre, Chambost, Hervé, Henriet, Céline, Susen, Sophie, Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Effilux, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Département d'Oncologie et Hématologie [Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), Laboratoire d'hématologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Assistance Publique - Hôpitaux de Marseille (APHM), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), CHU Toulouse [Toulouse], and Lucas, Nelly

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, medicine.medical_specialty, 030204 cardiovascular system & hematology, von Willebrand factor, 03 medical and health sciences, 0302 clinical medicine, Von Willebrand factor, post‐marketing, Internal medicine, Breakthrough bleeding, hemic and lymphatic diseases, Von Willebrand disease, Humans, Medicine, Childbirth, Prospective Studies, post-marketing, Marketing, Thrombotic risk, biology, business.industry, HAEMOSTASIS, clinical trial, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Original Articles, medicine.disease, 3. Good health, Clinical trial, von Willebrand Diseases, Tolerability, factor VIII, biology.protein, Female, Observational study, Original Article, France, medicine.symptom, business, von Willebrand disease
Abstract

International audience; Background A triple-secured plasma-derived von Willebrand factor (pdVWF) almost devoid of factor VIII (FVIII):WILFACTIN(R), was approved in France in 2003, and then in other countries for the treatment of patients with von Willebrand disease (VWD). Objective To investigate long-term safety and efficacy of the product in real-life over the first 5 post-approval years. Patients/Methods This prospective, observational, national post-marketing study (PMS) enrolled patients of all ages and VWD types. Patients were observed for up to 3 years and treated for one or more occasions. Efficacy was assessed for each major event. Breakthrough bleeding rate 3 days post-infusion and annualized bleeding rate (ABR) were also evaluated for long-term prophylaxis. Results Overall, 155 of 174 patients enrolled from 31 centers were eligible for efficacy assessment. Most patients (76.8%) were severely affected (VWF:RCo = 12 months. Excellent tolerability was confirmed with no safety concerns. No thrombotic events were observed. Conclusions Results from this PMS increase the clinical experience of a FVIII-poor pdVWF in patients of all ages and VWD types including those with thrombotic risk factors and emphasize that giving FVIII is not always mandatory to effectively treat patients with severe VWD.

Published
2020
Full Text
View/download PDF

9. A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease

Author

Veyradier, Agnès, Boisseau, Pierre, Fressinaud, Edith, Caron, Claudine, Ternisien, Catherine, Giraud, Mathilde, Zawadzki, Christophe, Trossaërt, Marc, Itzhar-Baikian, Nathalie, Dreyfus, Marie, D'Oiron, Roseline, Borel-Derlon, Annie, Susen, Sophie, Bézieau, Stéphane, Denis, Cecile, Goudemand, Jenny, von Willebrand disease, French Reference Center for, Gris, Jean-Christophe, Service d'hématologie biologique, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université Paris Diderot - Paris 7 (UPD7), Service de génétique médicale - Unité de génétique clinique [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bicêtre, Hémostase, Inflammation, Thrombose (HITH - U1176 Inserm - CHU Bicêtre), Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Hôpital cardiologique, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre hospitalier universitaire de Nantes (CHU Nantes), Laboratoire d'Hématologie Biologique [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Caractéristiques féminines des dysfonctions des interfaces cardio-vasculaires (EA 2992), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Herrada, Anthony, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), and Université Paris-Sud - Paris 11 (UP11)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Adult, Male, congenital, hereditary, and neonatal diseases and abnormalities, Adolescent, Genotype, Observational Study, Young Adult, hemic and lymphatic diseases, Humans, Child, Aged, Aged, 80 and over, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Infant, Middle Aged, von Willebrand Diseases, Phenotype, Child, Preschool, Mutation, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Female, France, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Research Article, circulatory and respiratory physiology
Abstract

Supplemental Digital Content is available in the text, von Willebrand disease (VWD) is a genetic bleeding disease due to a defect of von Willebrand factor (VWF), a glycoprotein crucial for platelet adhesion to the subendothelium after vascular injury. VWD include quantitative defects of VWF, either partial (type 1 with VWF levels

Published
2016
Full Text
View/download PDF

11. [Evaluation of a semi-automated test for quantification of von Willebrand multimers].

Author

Peronino C, Rivet N, Itzhar-Baikian N, Philippe A, Joly BS, de Bezieux JR, Martin AC, Luneau S, Veyradier A, Gaussem P, Gendron N, and Smadja DM

Subjects
Humans, Protein Multimerization, Automation, Laboratory standards, Automation, Laboratory methods, Automation, Laboratory instrumentation, von Willebrand Factor analysis, von Willebrand Diseases diagnosis, von Willebrand Diseases blood
Abstract

The assessment of von Willebrand factor (VWF) multimer distribution, particularly following the implantation of circulatory support devices, is a crucial parameter in hemostasis. Our study aimed to evaluate the semi-automated quantification of VWF multimers using the Sebia Hydrasys analyzer. Our analysis focused on quantifying high molecular weight, intermediate weight, and low molecular weight VWF multimers. Electrophoretic migration was performed using the Hydrasys 2 scan, and interpretation was carried out using densitometric analysis with the Phoresis software. The Hydrasys scan 2 successfully separated all the expected VWF multimer profiles based on the type of von Willebrand disease. The analysis revealed that in patients with circulatory support devices, elevated levels of plasma VWF rendered multimer migration unanalyzable using the methodology recommended by the manufacturer. Therefore, adjustment to a 100 % VWF antigenic level improved gel precision. We also suggest using as a standardized control the Cryocheck™ plasma, and have established reference values. Overall, this semi-automated, standardized, and optimized VWF multimer analysis system allows for an effective assessment of the VWF multimeric profile.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results